VibroSense Dynamics (VSD) Q5 24/25 summary

Executive summary

• Net sales for Q5 (July–September 2025) increased 18% year-over-year to SEK 512,055, driven by higher sales and rentals of diagnostic instruments.

• Net loss after financial items improved to SEK -1,109,318 from SEK -1,210,287, reflecting cost reductions and improved cost control.

• The company strengthened its organization with three new hires, including a Key Account Manager in China, and underwent a CEO transition.

• Patent granted for a biomarker to predict nerve damage risk during chemotherapy.

Financial highlights

• Q5 net sales: SEK 512,055 (up from SEK 431,801 year-over-year).

• Q5 net loss: SEK -1,109,318 (improved from SEK -1,210,287 year-over-year).

• 15-month net sales: SEK 2,433,069 (up from SEK 2,131,974 for the previous 12 months).

• 15-month net loss: SEK -5,958,634 (improved from SEK -7,668,669 for the previous 12 months).

• Cash and cash equivalents at period end: SEK 8,333,741.

Outlook and guidance

• Temporary revenue loss expected in the next quarters due to a terminated agreement with Avonova.

• Potential revenue growth anticipated if deliveries to China commence as planned.

• Increased marketing and sales efforts in EU and Asia, with a focus on direct sales in the EU and distributor partnerships in Asia.